APA

Westin J. R., Chu F., Zhang M., Fayad L. E., Kwak L. W., Fowler N., Romaguera J., Hagemeister F., Fanale M., Samaniego F., Feng L., Baladandayuthapani V., Wang Z., Ma W., Gao Y., Wallace M., Vence L. M., Radvanyi L., Muzzafar T., Rotem-Yehudar R., Davis R. E. & Neelapu S. S. (20140226). Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. : The Lancet. Oncology.

Chicago

Westin Jason R, Chu Fuliang, Zhang Min, Fayad Luis E, Kwak Larry W, Fowler Nathan, Romaguera Jorge, Hagemeister Fredrick, Fanale Michelle, Samaniego Felipe, Feng Lei, Baladandayuthapani Veerabhadran, Wang Zhiqiang, Ma Wencai, Gao Yanli, Wallace Michael, Vence Luis M, Radvanyi Laszlo, Muzzafar Tariq, Rotem-Yehudar Rinat, Davis R Eric and Neelapu Sattva S. 20140226. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. : The Lancet. Oncology.

Harvard

Westin J. R., Chu F., Zhang M., Fayad L. E., Kwak L. W., Fowler N., Romaguera J., Hagemeister F., Fanale M., Samaniego F., Feng L., Baladandayuthapani V., Wang Z., Ma W., Gao Y., Wallace M., Vence L. M., Radvanyi L., Muzzafar T., Rotem-Yehudar R., Davis R. E. and Neelapu S. S. (20140226). Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. : The Lancet. Oncology.

MLA

Westin Jason R, Chu Fuliang, Zhang Min, Fayad Luis E, Kwak Larry W, Fowler Nathan, Romaguera Jorge, Hagemeister Fredrick, Fanale Michelle, Samaniego Felipe, Feng Lei, Baladandayuthapani Veerabhadran, Wang Zhiqiang, Ma Wencai, Gao Yanli, Wallace Michael, Vence Luis M, Radvanyi Laszlo, Muzzafar Tariq, Rotem-Yehudar Rinat, Davis R Eric and Neelapu Sattva S. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. : The Lancet. Oncology. 20140226.